RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation boosts cancer drug in aggressive myeloma trial
Disease control Recruiting nowThis study tests whether low doses of radiation can make the drug elranatamab work better against a tough type of multiple myeloma that has come back or not responded to treatment. About 34 adults with extramedullary or paramedullary disease will receive radiation plus elranatama…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New drug duo aims to tame Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests whether combining two medicines, mezigdomide and elranatamab, can shrink tumors or slow disease in people with multiple myeloma that has come back or stopped responding to other treatments. About 75 adults will take part. The goal is to see how many patients achi…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New drug duo takes on hard-to-treat blood cancer
Disease control Recruiting nowThis study tests a new drug, REGN17372, combined with another drug, linvoseltamab, in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combination shrinks tumors better than linvoseltamab alone. About 15…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New drug combo aims to control Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study tests two drugs, mezigdomide and talquetamab, in people with multiple myeloma that has come back or not responded to treatment. The goal is to find the safest dose and see how well the combination controls the cancer. About 25 adults will take part, receivi…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Can a simple antiviral shield myeloma patients from a dangerous infection?
Disease control Recruiting nowThis study tests whether the antiviral drug letermovir can prevent serious CMV infections in people with relapsed/refractory multiple myeloma who are being treated with elranatamab. About 40 adult participants who have had CMV in the past will receive letermovir alongside their c…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New hope for myeloma: experimental drug linvoseltamab faces off against standard combo in phase 3 trial
Disease control Recruiting nowThis phase 3 study compares an experimental drug, linvoseltamab, to a standard three-drug combination (EPd) in people with multiple myeloma that has returned after 1-4 prior treatments. About 410 participants will be randomly assigned to receive either linvoseltamab or EPd. The m…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New shot combo aims to control hard-to-treat blood cancer
Disease control Recruiting nowThis study tests a new combination of two drugs (elranatamab and isatuximab) given as shots under the skin for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. About 30 adults will take part. The goal is to see if the combo c…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for Tough-to-Treat myeloma: epunamin combo trial launches
Disease control Recruiting nowThis study tests a new combination of drugs (epunamin plus DECP) in 48 adults with relapsed/refractory multiple myeloma, a blood cancer that has come back or stopped responding to treatment. The goal is to see if this combo can shrink tumors and improve outcomes. Participants mus…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Shanxi Bethune Hospital • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New study tracks how well myeloma drugs work in everyday practice
Knowledge-focused Recruiting nowThis study observes 900 patients with relapsed/refractory multiple myeloma who received teclistamab or talquetamab outside of clinical trials. Researchers will analyze how well these treatments work, how long benefits last, and what side effects occur. The goal is to understand r…
Matched conditions: RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC